How should I dose an adult patient with normal hepatic and renal function who requires pharmacologic treatment for both depression and anxiety?

Dosing Strategy for Comorbid Depression and Anxiety

Start with a single SSRI or SNRI at standard antidepressant doses, as these medications effectively treat both depression and anxiety disorders simultaneously, eliminating the need for separate "depression" and "anxiety" medications.

Recommended First-Line Approach

The most practical and evidence-based strategy is monotherapy with an SSRI or SNRI 1, 2. This approach works because:

• SSRIs and SNRIs are first-line treatments for both major depressive disorder and anxiety disorders (including generalized anxiety disorder, panic disorder, and social anxiety disorder)
• Using a single agent reduces polypharmacy risks, drug interactions, and side effect burden
• The same medication addresses both conditions at therapeutic antidepressant doses

Specific Medication Selection

SSRIs (choose one):

• Sertraline: Start 50 mg daily, target 100-200 mg daily
• Escitalopram: Start 10 mg daily, target 10-20 mg daily
• Paroxetine: Start 20 mg daily, target 20-50 mg daily
• Fluoxetine: Start 20 mg daily, target 20-60 mg daily

SNRIs (alternative option):

• Venlafaxine XR: Start 75 mg daily, target 150-225 mg daily 2
• Duloxetine: Start 30-60 mg daily, target 60-120 mg daily

Dosing Timeline

1. Weeks 0-2: Start at initial dose, monitor for tolerability
2. Weeks 2-4: Titrate to target therapeutic dose if tolerated
3. Weeks 4-8: Maintain therapeutic dose, assess response
4. Week 8+: If inadequate response, consider dose optimization before switching or augmenting

Critical Pitfalls to Avoid

Do NOT routinely add benzodiazepines as a separate "anxiety medication." While older literature 3 suggested combining benzodiazepines with antidepressants for rapid symptom relief, current guidelines 4 recommend benzodiazepines only for:

• Short-term use (maximum 2-4 weeks) during SSRI/SNRI initiation if severe anxiety/agitation
• Specific indications like catatonic depression or acute suicidality
• They should be tapered after 4 weeks once the antidepressant takes effect

Do NOT use separate medications for depression versus anxiety unless monotherapy fails. The evidence shows no recommendation for routine combination therapy 2.

When Monotherapy Fails

If inadequate response after 8-12 weeks at therapeutic doses 1:

Second-step options include:

• Switching to a different SSRI/SNRI
• Augmentation with atypical antipsychotics (aripiprazole, brexpiprazole, quetiapine XR) 5
• Adding evidence-based psychotherapy (CBT) 2

The evidence for switching versus augmenting strategies shows similar efficacy 1, so base the decision on:

• Degree of initial response (partial response → augment; no response → switch)
• Tolerability of current medication
• Patient preference

Key Evidence Considerations

The 2023 guidelines 1, 2 consistently support SSRIs/SNRIs as first-line pharmacotherapy, though the certainty of evidence is rated as low. Despite this limitation, these remain the most reliable evidence-based options. The Japanese anxiety guidelines 2 specifically found no evidence supporting routine combination of pharmacotherapy and psychotherapy over monotherapy, though CBT can be added if medication alone is insufficient.

Bottom line: Treat both conditions with one medication at full antidepressant doses, not two separate medications for "depression" and "anxiety."